Archemix Corporation

Novartis Ag

Arrowhead Pharmaceuticals, Inc.

Baxter International Inc.

Baxter Healthcare Sa

Arrowhead Research Corporation

Baxalta Gmbh

John Louis Diener

Gregory Hinkle

Stuart Milstein

Antonin De Fougerolles

Emma Hickman

Anne-Marie Pulichino

Andrew Griffin Sprague

Charles Wilson

David Epstein

Thomas Greene McCauley

Claude Benedict

Jeffrey C Kurz

Dilara Grate

Kristin Thompson

H A Daniel Lagassé

Markus Kurz

Anthony Dominic Keefe

Kathleen McGinness

Robert Schaub

Jennifer Nelson

Ryan Genga

Emily Waters

Sara Chesworth Keene

Jun Yuan

Frederic Zecri

Sharon T Cload

Sarah Williams

James Rottman

Scott Louis Cohen

Kathrin Ladetzki-Baehs

David Barnes-Seeman

Michael John Romanowski

Lars Gadtke

Cesare Russo

Jess Wagner-Whyte

Chunhua Wang

Amy White

Dilara McCauley

Martin Stanton

Paul Hatala

Thomas Mccauley

Xenia Karola Wezler

Felix Hartlepp

James Roache

Anna J Zoltoski

Christian Gampe

Tiancen Hu

Xiaoling Xie

David J Fontana

Paula Burmeister

Harold Nicholas Marsh

Pooja Sawhney

Dilârâ McCauley

Shuhao Zhu

Robert G Schaub

Jiaping Gao

Errol Desouza

Rick Jerome Schiebinger

Thomas Green Mccauley

Jeffrey Preiss

This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.

Natriuretic peptide receptor 1 antibodies and methods of use

The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.

Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant FC fusion proteins

The disclosure relates to nucleic acids that contain modifications at the 5'-end, 3&#x2032;-end or 5&#x2032;-end and 3&#x2032;-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.

3' end caps, 5&#x2032; end caps and combinations thereof for therapeutic RNA

The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

Organic compositions to treat beta-ENaC-related diseases

Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.

Aptamers comprising CPG motifs

Organic compositions to treat Beta-ENaC-related diseases

The present disclosure relates to RNAi agents useful in methods of treating BetaENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

Methods are provided for identifying aptamer regulators. Aptamer regulators are aptamers that bind to a target wherein binding of the aptamer regulator to the target increases the binding affinity of the target for a target partner relative to the affinity of the target for the target partner when the target is not bound by the aptamer regulator such that binding of the aptamer regulator to the target is a prerequisite for target-target partner complex formation.

Methods for identifying aptamer regulators

Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics

The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics

Growing community of inventors

Cambridge, MA, United States of America

John Louis Diener